【文章名】Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4(+) Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients
Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4(+) Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients
[摘要]：Introduction. The impact of highly active antiretroviral therapy (HAART) on CD4+ cell course during treatment with pegylated interferon plus ribavirin (PegIFN-RBV) in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is unknown. Methods. We determined CD4(+) cell count in 94 HIV-HCV coinfected patients undergoing treatment with pegylated interferon plus RBV at baseline, treatment weeks 4-48 (W4-W48), and months 1, 3, and 6 of follow-up. Of the 94 patients, 70 underwent concomitant HAART (group A) and 24 did not (group B). Results. Group A showed smaller CD4(+) cell decreases from W24-W48 (P = .027) and greater CD4(+) cell increases after cessation of pegylated interferon plus ribavirin therapy (P = .002) than group B showed. Conclusions. Concomitant HAART leads to smaller decreases and faster recovery of CD4(+) cells during and after pegylated interferon plus RBV therapy.
